Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Ghassan K. Abou‐Alfa; George Lau; Masatoshi Kudo; Stephen L. Chan; Robin Kate Kelley; Junji Furuse; Wattana Sukeepaisarnjaroen; Yoon‐Koo Kang; Tu Van Dao; Enrico N. De Toni; Lorenza Rimassa; В. В. Бредер; Alexander Vasilyev; Alexandra Heurgué; Vincent C. Tam; Kabir Mody; Satheesh Chiradoni Thungappa; Yurii Ostapenko; Thomas Yau; Sérgio Jobim Azevedo; Marı́a Varela; Ann‐Lii Cheng; Shukui Qin; Peter R. Galle; Sajid Ali; Charu Gupta; Mallory Makowsky; John F. Kurland; Alejandra Negro; Bruno Sangro

doi:10.2217/fon-2023-0486

Related publications

Article2022

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle, Sajid Ali, Michelle Marcovitz, Mallory Makowsky, Philip He, John F. Kurland, Alejandra Negro, Bruno Sangro

Article2024

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

George Lau, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao, Yoon‐Koo Kang, C. Satheesh, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong‐Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Sérgio Jobim Azevedo, María Reig, Éric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky,

Article2023

Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Marie‐Luise Berres, Stephen L. Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong‐Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Ann-Li Cheng, Sérgio Santos de Azevêdo, María Reig, Éric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky, Di Ran, Alejandra Negro, Ghassan K. Abou‐Alfa

Article2024

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, ,

Article2025

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial

George Lau, Bruno Sangro, Ann‐Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, María Reig, Ho Yeong Lim, David Tougeron, Enrico N. De Toni, Vincent C. Tam, Kabir Mody, Jun Gong, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Lipatov, Manabu Morimoto, Isabelle Archambeaud, Valentina Burgio, Le Thi Tuyet Phuong,